Basilea reports acceptance for regulatory review of Pfizer’s marketing authorization application for antifungal isavuconazole (...
Second indication under review following mucormycosis Basel, Switzerland, November 25, 2020 Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that the marketing authorization application (MAA) for the antifungal isavuconazole (Cresemba®) for the …